Related Experiment Videos
Assisted circulation for end-stage chronic heart failure
1Consejo Nacional de Investigaciones Cientificas Y Tecnicas, Facultad de Medicine, Universidad de Morón, Buenos Aires, Argentina.
Artificial Organs
|April 4, 1998
Summary
The ProCor Model 1 pneumatic left ventricular assist device (LVAD) offers a compact, durable solution for end-stage heart failure. Its design supports prolonged circulatory assistance by synchronizing with the patient's ECG.
Area of Science:
- Cardiovascular Engineering
- Biomedical Devices
- Heart Failure Therapy
Background:
- Electromechanical left ventricular assist devices (LVADs) are prevalent, but pneumatic systems offer unique advantages.
- End-stage chronic heart failure necessitates advanced circulatory support solutions.
- The ProCor Model 1 represents a novel pneumatic LVAD system.
Purpose of the Study:
- To describe the design and functionality of the ProCor Model 1 pneumatic LVAD.
- To highlight its features for prolonged circulatory assistance in heart failure patients.
- To present its potential role as an alternative to existing LVAD technologies.
Main Methods:
- The ProCor Model 1 features a compact, double-pusher plate implantable pump and a small, portable power pack.
- The device synchronizes with the electrocardiogram (ECG) to pump during the diastolic period.
- A multipurpose pneumatic tube integrates ECG sensing and pacing capabilities, alongside a porcine bioprosthesis.
Main Results:
- The system is designed for constant driving conditions: 60 bpm rate, 25% systolic duration, 1,800 mm Hg/s dP/dt, and 250 mm Hg driving pressure.
- This configuration achieves a basic pump output of 3.500 L/min for sustained circulatory support.
- The integrated pneumatic tube allows for potential cardiac pacing if required.
Conclusions:
- The ProCor Model 1 pneumatic LVAD demonstrates potential for long-lasting, compact circulatory assistance.
- Its design incorporates advanced features for enhanced patient management and support.
- This pneumatic system offers a viable alternative in the treatment of end-stage chronic heart failure.